Browse the corpus

©2013 UpToDate ® Print Email Prognostic scoring systems for newly diagnosted chronic myeloid leukemia* Scoring system Variables Equation for relative risk of progression Calculator Risk groups Sokal Score [1] Spleen size • : 0.0345(spleen - 7.51 cm) Relative risk calculated as the exponential of the total obtained from the variables adjusted by weight. λ i (t)/λ o (t) = EXP 0.0116(age - 43.4) + 0.0345(spleen - 7.51) + 0.188[(platelets/700) 2 - 0.563] + 0.0887(blasts - 2.10) A Sokal risk score calculator is available online at: www.roc.se/sokal.asp Low risk: relative risk <0.8 Percentage blasts Δ : 0.887(myeloblasts - 2.10) Intermediate risk: relative risk 0.8 to 1.2 Age: 0.116(age - 43.4 years) High risk: relative risk >1.2 Platelet count: 0.118[(platelets/700) 2 - 0.563] Euro (Hasford) Score [2] Spleen size • : 0.042(spleen in cm below costal margin) Relative risk calculated as the total obtained from the variables adjusted by weight and then multiplied by 1000. A Euro score calculator is available online at: file://www.leukemia-net.org/content/leukemias/cml/cml_score/ Low risk: score ≤780 Percentage blasts Δ : 0.0584(myeloblasts) Intermediate risk: score >780 and ≤1480 Age: 0.666 when age ≥50 years High risk: score >1480 Platelet count: 1.0956 when ≥1500 x 10 9 /L Percentage eosinophils Δ : 0.0413(eosinophils) Percentage basophils Δ : 0.20399 when basophils ≥3 percent EUTOS Score [3] Percentage basophils Δ Relative risk calculated as 7(basophils) + 4(spleen size) A EUTOS score calculator is available online at: file://www.leukemia-net.org/content/leukemias/cml/eutos_score/ Low risk: sum ≤87 Spleen size • : measured in centimeters below the costal margin High risk: >87 * These scoring systems were designed for patients with newly diagnosed CML who have not yet received any treatment, including hydroxyurea. In addition, the EUTOS score was specifically designed to predict outcomes among patients undergoing initial treatment with imatinib. • Spleen size as assessed by physical examination. Δ Percentage blasts, basophils, and eosinophils are measured from peripheral blood. References: Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984; 63:789.

* These scoring systems were designed for patients with newly diagnosed CML who have not yet received any treatment, including hydroxyurea. In addition, the EUTOS score was specifically designed to predict outcomes among patients undergoing initial treatment with imatinib. • Spleen size as assessed by physical examination. Δ Percentage blasts, basophils, and eosinophils are measured from peripheral blood. References: Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984; 63:789. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90:850. Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118:686.